相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Screening of Male Dialysis Patients for Fabry Disease by Plasma Globotriaosylsphingosine
Hiroki Maruyama et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease
Michel Boutin et al.
CLINICA CHIMICA ACTA (2012)
Pharmacological chaperone therapy for Fabry disease
Satoshi Ishii
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2012)
Increased globotriaosylceramide levels in a transgenic mouse expressing human α1,4-galactosyltransferase and a mouse model for treating Fabry disease
Chikara Shiozuka et al.
JOURNAL OF BIOCHEMISTRY (2011)
IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease
Marianna Sadagurski et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease
Karen M. Ashe et al.
PLOS ONE (2011)
Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease
S. M. Rombach et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease
John Marshall et al.
PLOS ONE (2010)
Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion
Karin G. Gerritsen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury
Felix Heymann et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease
Satoshi Ishii et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria
Camilla Tondel et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice
Ying Sun et al.
HUMAN MOLECULAR GENETICS (2008)
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
Johannes M. Aerts et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Effective cell and gene therapy in a murine model of Gaucher disease
Ida Berglin Enquist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Lysosomal storage diseases: Natural history and ethical and economic aspects
Ernest Beutler
MOLECULAR GENETICS AND METABOLISM (2006)
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
R Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
An in vitro model of Fabry disease
LM Shu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy
JS Shah et al.
ACTA PAEDIATRICA (2005)
α-Galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency
PF Bodary et al.
CIRCULATION (2005)
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
A Mehta et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Transgenic mouse expressing human mutant α-galactosidase A in an endogenous enzyme deficient background:: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease
S Ishii et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2004)
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
GE Linthorst et al.
KIDNEY INTERNATIONAL (2004)
Early detection of Fabry cardiomyopathy by tissue Doppler imaging
M Pieroni et al.
CIRCULATION (2003)
Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis
DT Eitzman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression
PK Stricklett et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin
PB Eisenhauer et al.
INFECTION AND IMMUNITY (2001)
Fabry disease: Preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice
YA Ioannou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells
T Takenaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation
A Abe et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
T Cox et al.
LANCET (2000)
分享论文
